ReviewMolecular biomedicine2022
CRISPR-Cas systems target endogenous genes to impact bacterial physiology and alter mammalian immune responses.
Review in Molecular biomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- CRISPR application in hematological disorders: from bench to bedside.Blood advances · 2026Review
- Major type IV pilin ofmBio · 2026Article
- Characterization of CRISPR-Cas systems in the Haemophilus genus CRISPR-Cas in Haemophilus spp.Genetics and molecular biology · 2026Article
- A Critical Review of Quorum-Sensing Inhibition Strategies in Klebsiella Pneumoniae.Current microbiology · 2025Review
- Occurrence of CRISPR-Cas genes and lack of association with antibiotic resistance in Shigella isolates collected from patients with diarrhea in Ahvaz, southwest Iran.BMC infectious diseases · 2025Article
- Antibiotic Alternatives and Next-Generation Therapeutics forAntibiotics (Basel, Switzerland) · 2025Review
- The Bioengineering of Insect Cell Lines for Biotherapeutics and Vaccine Production: An Updated Review.Vaccines · 2025Review
- Multidrug resistance in Pseudomonas aeruginosa: genetic control mechanisms and therapeutic advances.Molecular biomedicine · 2024Review
- Combating antimicrobial resistance in osteoarticular infections: Current strategies and future directions.Journal of clinical orthopaedics and trauma · 2024Review
- CRISPR-Cas system positively regulates virulence of Salmonella enterica serovar Typhimurium.Gut pathogens · 2024Article
- Comparative genomic analysis identifies potential adaptive variation inMicrobial genomics · 2024Article
- Comprehensive analysis of the CRISPR-Cas systems in Streptococcus thermophilus strains isolated from traditional yogurts.Antonie van Leeuwenhoek · 2024Article
- Endogenous Type I-C CRISPR-Cas system ofFrontiers in microbiology · 2024Article
- Microbial Biofilms: Applications, Clinical Consequences, and Alternative Therapies.Microorganisms · 2023Review
- CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.ACS infectious diseases · 2023Review
- The Phylogenetic Study of the CRISPR-Cas System in Enterobacteriaceae.Current microbiology · 2023Article
- Association of CRISPR-Cas System with the Antibiotic Resistance and Virulence Genes in Nosocomial Isolates ofInfection and drug resistance · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
CRISPR-Cas systems are an immune defense mechanism that is widespread in archaea and bacteria against invasive phages or foreign genetic elements. In the last decade, CRISPR-Cas systems have been a leading gene-editing tool for agriculture (plant engineering), biotechnology, and human health (e.g., diagnosis and treatment of cancers and genetic diseases), benefitted from unprecedented discoveries of basic bacterial research. However, the functional complexity of CRISPR systems is far beyond the original scope of immune defense. CRISPR-Cas systems are implicated in influencing the expression of physiology and virulence genes and subsequently altering the formation of bacterial biofilm, drug resistance, invasive potency as well as bacterial own physiological characteristics. Moreover, increasing evidence supports that bacterial CRISPR-Cas systems might intriguingly influence mammalian immune responses through targeting endogenous genes, especially those relating to virulence; however, unfortunately, their underlying mechanisms are largely unclear. Nevertheless, the interaction between bacterial CRISPR-Cas systems and eukaryotic cells is complex with numerous mysteries that necessitate further investigation efforts. Here, we summarize the non-canonical functions of CRISPR-Cas that potentially impact bacterial physiology, pathogenicity, antimicrobial resistance, and thereby altering the courses of mammalian immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.